Search research articles
Contact Us
Filters
Showing results (151-160 of 227) with videos related to
Page
of 23
Sort By:
American Heart Journal
|
April 30, 2017
Balancing the risk of spontaneous ischemic and major bleeding events in acute coronary syndromes
Gregory Ducrocq, Phillip J Schulte, Andrzej Budaj, et al.
American Heart Journal
|
December 3, 2014
Vorapaxar with or without clopidogrel after non-ST-segment elevation acute coronary syndromes: results from the thrombin receptor antagonist for clinical event reduction in acute coronary syndrome trial
Pierluigi Tricoci, Yuliya Lokhnygina, Zhen Huang, et al.
American Heart Journal
|
August 10, 2016
Effect of age on efficacy and safety of vorapaxar in patients with non-ST-segment elevation acute coronary syndrome: Insights from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) trial
Luciana V Armaganijan, Karen P Alexander, Zhen Huang, et al.
American Heart Journal
|
June 4, 2018
Safety of ticagrelor in patients with baseline conduction abnormalities: A PLATO (Study of Platelet Inhibition and Patient Outcomes) analysis
Benjamin M Scirica, Sameer Bansilal, Farideh Davoudi, et al.
American Heart Journal
|
June 23, 2014
Extent of coronary artery disease and outcomes after ticagrelor administration in patients with an acute coronary syndrome: Insights from the PLATelet inhibition and patient Outcomes (PLATO) trial
Anna Kotsia, Emmanouil S Brilakis, Claes Held, et al.
The American Journal of Cardiology
|
March 18, 2015
Glycoprotein IIb/IIIa Receptor Inhibitors in Combination With Vorapaxar, a Platelet Thrombin Receptor Antagonist, Among Patients With Non-ST-Segment Elevation Acute Coronary Syndromes (from the TRACER Trial)
Jan H Cornel, Pierluigi Tricoci, Yuliya Lokhnygina, et al.
The American Journal of Cardiology
|
June 6, 2024
Cardiometabolic Co-morbidity Burden and Circulating Biomarkers in Patients With Chronic Coronary Disease in the ISCHEMIA Trials
Carine E Hamo, Richard Liu, Wenbo Wu, et al.
American Heart Journal
|
May 16, 2016
History of bleeding and outcomes with apixaban versus warfarin in patients with atrial fibrillation in the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation trial
Raffaele De Caterina, Ulrika Andersson, John H Alexander, et al.
Circulation
|
October 31, 2013
Biomarkers in relation to the effects of ticagrelor in comparison with clopidogrel in non-ST-elevation acute coronary syndrome patients managed with or without in-hospital revascularization: a substudy from the Prospective Randomized Platelet Inhibition and Patient Outcomes (PLATO) trial
Lars Wallentin, Daniel Lindholm, Agneta Siegbahn, et al.
The New England Journal of Medicine
|
September 1, 2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes
Lars Wallentin, Richard C Becker, Andrzej Budaj, et al.
Page
of 23
Search research articles
Search
Showing results (151-160 of 227) with videos related to
Sort By:
Page
of 23
American Heart Journal
|
April 30, 2017
Balancing the risk of spontaneous ischemic and major bleeding events in acute coronary syndromes
Gregory Ducrocq, Phillip J Schulte, Andrzej Budaj, et al.
American Heart Journal
|
December 3, 2014
Vorapaxar with or without clopidogrel after non-ST-segment elevation acute coronary syndromes: results from the thrombin receptor antagonist for clinical event reduction in acute coronary syndrome trial
Pierluigi Tricoci, Yuliya Lokhnygina, Zhen Huang, et al.
American Heart Journal
|
August 10, 2016
Effect of age on efficacy and safety of vorapaxar in patients with non-ST-segment elevation acute coronary syndrome: Insights from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) trial
Luciana V Armaganijan, Karen P Alexander, Zhen Huang, et al.
American Heart Journal
|
June 4, 2018
Safety of ticagrelor in patients with baseline conduction abnormalities: A PLATO (Study of Platelet Inhibition and Patient Outcomes) analysis
Benjamin M Scirica, Sameer Bansilal, Farideh Davoudi, et al.
American Heart Journal
|
June 23, 2014
Extent of coronary artery disease and outcomes after ticagrelor administration in patients with an acute coronary syndrome: Insights from the PLATelet inhibition and patient Outcomes (PLATO) trial
Anna Kotsia, Emmanouil S Brilakis, Claes Held, et al.
The American Journal of Cardiology
|
March 18, 2015
Glycoprotein IIb/IIIa Receptor Inhibitors in Combination With Vorapaxar, a Platelet Thrombin Receptor Antagonist, Among Patients With Non-ST-Segment Elevation Acute Coronary Syndromes (from the TRACER Trial)
Jan H Cornel, Pierluigi Tricoci, Yuliya Lokhnygina, et al.
The American Journal of Cardiology
|
June 6, 2024
Cardiometabolic Co-morbidity Burden and Circulating Biomarkers in Patients With Chronic Coronary Disease in the ISCHEMIA Trials
Carine E Hamo, Richard Liu, Wenbo Wu, et al.
American Heart Journal
|
May 16, 2016
History of bleeding and outcomes with apixaban versus warfarin in patients with atrial fibrillation in the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation trial
Raffaele De Caterina, Ulrika Andersson, John H Alexander, et al.
Circulation
|
October 31, 2013
Biomarkers in relation to the effects of ticagrelor in comparison with clopidogrel in non-ST-elevation acute coronary syndrome patients managed with or without in-hospital revascularization: a substudy from the Prospective Randomized Platelet Inhibition and Patient Outcomes (PLATO) trial
Lars Wallentin, Daniel Lindholm, Agneta Siegbahn, et al.
The New England Journal of Medicine
|
September 1, 2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromes
Lars Wallentin, Richard C Becker, Andrzej Budaj, et al.
Page
of 23